Celgene (CELG) Hits 52-Week High, Can the Run Continue?
Shares of Celgene (CELG) have been strong performers lately, with the stock up 9.8% over the past month. The stock hit a new 52-week high of $109.75 in the previous session. Celgene has gained 70.9% since the start of the year compared to the 4.1% move for the Zacks Medical sector and the 2.9% return for the Zacks Medical - Biomedical and Genetics industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on October 31, 2019, Celgene reported EPS of $2.99 versus consensus estimate of $2.73 while it beat the consensus revenue estimate by 1.72%.
For the current fiscal year, Celgene is expected to post earnings of $10.99 per share on $17.55 billion in revenues. This represents a 23.9% change in EPS on a 14.84% change in revenues. For the next fiscal year, the company is expected to earn $12.06 per share on $18.94 billion in revenues. This represents a year-over-year change of 9.71% and 7.95%, respectively.
Celgene may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Celgene has a Value Score of A. The stock's Growth and Momentum Scores are B and B, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 10X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 12.4X versus its peer group's average of 13.1X. Additionally, the stock has a PEG ratio of 0.5. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Celgene currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Celgene passes the test. Thus, it seems as though Celgene shares could still be poised for more gains ahead.
How Does Celgene Stack Up to the Competition?
Shares of Celgene have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also looking good, including Genomic Health (GHDX), Alexion Pharmaceuticals (ALXN), and Regeneron Pharmaceuticals (REGN), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.
The Zacks Industry Rank is in the top 25% of all the industries we have in our universe, so it looks like there are some nice tailwinds for Celgene, even beyond its own solid fundamental situation.
Click to get this free report
Celgene Corporation (CELG): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.